REDUCING GLOBAL PERIOPERATIVE RISK
This resource center is jointly hosted by The American Journal of Medicine,
The American Journal of Cardiology, and the Canadian Journal of Cardiology.
Key Findings
- Compared to placebo, the use of dabigatran reduced major vascular complications (ie, a composite of vascular mortality, nonfatal MI, non-hemorrhagic stroke, peripheral arterial thrombosis, amputation, and symptomatic VTE) by a hazard ratio of 0.72.
- In terms of primary safety outcome (i.e. a composite of life-threatening, major, and critical organ bleed), there was no significant difference between dabigatran and placebo.
- MANAGE demonstrated that the use of dabigatran could prevent major vascular complications with no observed increased risk of major bleeding.
Key Term:
Tab Section:
Key Column Display :
Right Column
